Cargando…

Critically Ill COVID-19 Patients Show Reduced Point of Care-Measured Butyrylcholinesterase Activity—A Prospective, Monocentric Observational Study

A biomarker for risk stratification and disease severity assessment in SARS-CoV-2 infections has not yet been established. Point of care testing (POCT) of butyrylcholinesterase (BChE) enables early detection of systemic inflammatory responses and correlates with disease severity in sepsis and burns....

Descripción completa

Detalles Bibliográficos
Autores principales: Espeter, Florian, Künne, David, Garczarek, Lena, Kuhlmann, Henning, Skarabis, Annabell, Zivkovic, Aleksandar R., Brenner, Thorsten, Schmidt, Karsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9498245/
https://www.ncbi.nlm.nih.gov/pubmed/36140551
http://dx.doi.org/10.3390/diagnostics12092150
_version_ 1784794710480519168
author Espeter, Florian
Künne, David
Garczarek, Lena
Kuhlmann, Henning
Skarabis, Annabell
Zivkovic, Aleksandar R.
Brenner, Thorsten
Schmidt, Karsten
author_facet Espeter, Florian
Künne, David
Garczarek, Lena
Kuhlmann, Henning
Skarabis, Annabell
Zivkovic, Aleksandar R.
Brenner, Thorsten
Schmidt, Karsten
author_sort Espeter, Florian
collection PubMed
description A biomarker for risk stratification and disease severity assessment in SARS-CoV-2 infections has not yet been established. Point of care testing (POCT) of butyrylcholinesterase (BChE) enables early detection of systemic inflammatory responses and correlates with disease severity in sepsis and burns. In acute care or resource-limited settings, POCT facilitates rapid clinical decision making, a particularly beneficial aspect in the management of pandemic situations. In this prospective observational study, POCT-measured BChE activity was assessed in 52 critically ill COVID-19 patients within 24 h of ICU admission and on the third and seventh day after ICU admission. Forty (77%) of these patients required venovenous extracorporeal membrane oxygenation (vvECMO). In critically ill COVID-19 patients, BChE activity is significantly decreased compared with healthy subjects, but also compared with other inflammatory conditions such as sepsis, burns, or trauma. POCT BChE activity reflects the severity of organ dysfunction and allows prediction of 28-day mortality in critically ill COVID-19 patients. Implementing early POCT BChE measurement could facilitate risk stratification and support admission and transfer decisions in resource-limited settings.
format Online
Article
Text
id pubmed-9498245
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94982452022-09-23 Critically Ill COVID-19 Patients Show Reduced Point of Care-Measured Butyrylcholinesterase Activity—A Prospective, Monocentric Observational Study Espeter, Florian Künne, David Garczarek, Lena Kuhlmann, Henning Skarabis, Annabell Zivkovic, Aleksandar R. Brenner, Thorsten Schmidt, Karsten Diagnostics (Basel) Article A biomarker for risk stratification and disease severity assessment in SARS-CoV-2 infections has not yet been established. Point of care testing (POCT) of butyrylcholinesterase (BChE) enables early detection of systemic inflammatory responses and correlates with disease severity in sepsis and burns. In acute care or resource-limited settings, POCT facilitates rapid clinical decision making, a particularly beneficial aspect in the management of pandemic situations. In this prospective observational study, POCT-measured BChE activity was assessed in 52 critically ill COVID-19 patients within 24 h of ICU admission and on the third and seventh day after ICU admission. Forty (77%) of these patients required venovenous extracorporeal membrane oxygenation (vvECMO). In critically ill COVID-19 patients, BChE activity is significantly decreased compared with healthy subjects, but also compared with other inflammatory conditions such as sepsis, burns, or trauma. POCT BChE activity reflects the severity of organ dysfunction and allows prediction of 28-day mortality in critically ill COVID-19 patients. Implementing early POCT BChE measurement could facilitate risk stratification and support admission and transfer decisions in resource-limited settings. MDPI 2022-09-03 /pmc/articles/PMC9498245/ /pubmed/36140551 http://dx.doi.org/10.3390/diagnostics12092150 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Espeter, Florian
Künne, David
Garczarek, Lena
Kuhlmann, Henning
Skarabis, Annabell
Zivkovic, Aleksandar R.
Brenner, Thorsten
Schmidt, Karsten
Critically Ill COVID-19 Patients Show Reduced Point of Care-Measured Butyrylcholinesterase Activity—A Prospective, Monocentric Observational Study
title Critically Ill COVID-19 Patients Show Reduced Point of Care-Measured Butyrylcholinesterase Activity—A Prospective, Monocentric Observational Study
title_full Critically Ill COVID-19 Patients Show Reduced Point of Care-Measured Butyrylcholinesterase Activity—A Prospective, Monocentric Observational Study
title_fullStr Critically Ill COVID-19 Patients Show Reduced Point of Care-Measured Butyrylcholinesterase Activity—A Prospective, Monocentric Observational Study
title_full_unstemmed Critically Ill COVID-19 Patients Show Reduced Point of Care-Measured Butyrylcholinesterase Activity—A Prospective, Monocentric Observational Study
title_short Critically Ill COVID-19 Patients Show Reduced Point of Care-Measured Butyrylcholinesterase Activity—A Prospective, Monocentric Observational Study
title_sort critically ill covid-19 patients show reduced point of care-measured butyrylcholinesterase activity—a prospective, monocentric observational study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9498245/
https://www.ncbi.nlm.nih.gov/pubmed/36140551
http://dx.doi.org/10.3390/diagnostics12092150
work_keys_str_mv AT espeterflorian criticallyillcovid19patientsshowreducedpointofcaremeasuredbutyrylcholinesteraseactivityaprospectivemonocentricobservationalstudy
AT kunnedavid criticallyillcovid19patientsshowreducedpointofcaremeasuredbutyrylcholinesteraseactivityaprospectivemonocentricobservationalstudy
AT garczareklena criticallyillcovid19patientsshowreducedpointofcaremeasuredbutyrylcholinesteraseactivityaprospectivemonocentricobservationalstudy
AT kuhlmannhenning criticallyillcovid19patientsshowreducedpointofcaremeasuredbutyrylcholinesteraseactivityaprospectivemonocentricobservationalstudy
AT skarabisannabell criticallyillcovid19patientsshowreducedpointofcaremeasuredbutyrylcholinesteraseactivityaprospectivemonocentricobservationalstudy
AT zivkovicaleksandarr criticallyillcovid19patientsshowreducedpointofcaremeasuredbutyrylcholinesteraseactivityaprospectivemonocentricobservationalstudy
AT brennerthorsten criticallyillcovid19patientsshowreducedpointofcaremeasuredbutyrylcholinesteraseactivityaprospectivemonocentricobservationalstudy
AT schmidtkarsten criticallyillcovid19patientsshowreducedpointofcaremeasuredbutyrylcholinesteraseactivityaprospectivemonocentricobservationalstudy